Reportlinker Adds Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

Oct 21, 2010, 10:20 ET from Reportlinker

NEW YORK, Oct. 21 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

http://www.reportlinker.com/p0316115/Commercializing-Cancer-Drugs-Affecting-Angiogenesis-A-Decision-Support-Tool-for-Optimizing-the-Pipeline.htm

This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis approach for the treatment of cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3

2 About Cancer Highlights™ 4

2.1 Cancer Focus Areas 4

2.2 Subscribe Today and Start Saving 5

2.2.1 Type of License 5

2.3 BioSeeker Group's Oncology Team 5

3 Methodology 6

3.1 Cancer Highlights'™ Five Pillar Drug Assessment 6

4 Table of Contents 8

4.1 List of Figures 20

4.2 List of Tables 20

5 Introduction 35

5.1 The Scope of this Report 35

5.2 Definitions 38

5.3 Abbreviations 38

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 39

6.1 Drug Repositioning in Oncology 39

6.2 Introduction to Targets of Angiogenesis in Oncology 40

6.2.1 Calcium Ion Binding Targets 43

6.2.2 Carboxy-lyase Activity Targets 44

6.2.3 Catalytic Activity Targets 45

6.2.4 Cell Adhesion Molecule Activity Targets 50

6.2.5 Chaperone Activity Targets 56

6.2.6 Chemokine Activity Targets 60

6.2.7 Cofactor Binding Targets 61

6.2.8 Cysteine-type Peptidase Activity Targets 63

6.2.9 Cytokine Activity Targets 66

6.2.10 Cytoskeletal Protein Binding Targets 70

6.2.11 DNA topoisomerase Activity Targets 71

6.2.12 DNA-directed DNA Polymerase Activity Targets 73

6.2.13 Extracellular Matrix Structural Constituent Targets 74

6.2.14 G-protein Coupled Receptor Activity Targets 79

6.2.15 Growth Factor Activity Targets 84

6.2.16 GTPase Activity Targets 94

6.2.17 Hormone Activity Targets 97

6.2.18 Hydrolase Activity Targets 98

6.2.19 Kinase Activity Targets 99

6.2.20 Kinase Binding Targets 101

6.2.21 Lipid Kinase Activity Targets 102

6.2.22 Metallopeptidase Activity Targets 108

6.2.23 Motor Activity Targets 120

6.2.24 Oxidoreductase Activity Targets 121

6.2.25 Peptidase Activity Targets 123

6.2.26 Phosphoric Diester Hydrolase Activity Targets 139

6.2.27 Protease Inhibitor Activity Targets 141

6.2.28 Protein Binding Targets 145

6.2.29 Protein Serine/Threonine Kinase activity Targets 148

6.2.30 Protein-tyrosine Kinase Activity Targets 175

6.2.31 Receptor Activity Targets 185

6.2.32 Receptor Binding Targets 206

6.2.33 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 211

6.2.34 RNA Binding Targets 213

6.2.35 Serine-type Peptidase Activity Targets 214

6.2.36 Structural Constituent of Cytoskeleton Targets 218

6.2.37 Superoxide Dismutase Activity Targets 219

6.2.38 Transcription Factor Activity Targets 221

6.2.39 Transcription Regulator Activity Targets 230

6.2.40 Transferase Activity Targets 237

6.2.41 Translation Regulator Activity Targets 239

6.2.42 Transmembrane Receptor Activity Targets 244

6.2.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 246

6.2.44 Transporter Activity Targets 287

6.2.45 Ubiquitin-specific Protease Activity Targets 291

6.2.46 Voltage-gated Ion Channel Activity Targets 292

6.3 The Cancer Genome Project and Targets of Cancer Drugs Affecting Angiogenesis 293

6.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 293

6.4 Structure-based Drug Design in Cancer Angiogenesis Therapeutics is Stimulated by Available Structure Data on Biological Targets 298

6.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology 302

6.6 The Drug-Target Interactome 307

6.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Cancer Drugs 312

6.8 Pathway Assessment of Angiogenesis Affecting Targets in Oncology 316

6.8.1 Tools for Analysis of Cancer Pathways 317

6.8.2 Pathway Assessment 318

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development 367

7.1 Drug Target Strategies of Terminated Cancer Drugs Affecting Angiogenesis 369

7.2 Registered to Marketed: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 374

7.3 Phase III Clinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 376

7.4 Phase II Clinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 380

7.5 Phase I Clinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 388

7.6 Preclinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 397

7.7 No Development Data: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 401

7.8 Development Profiles of All Cancer Drugs Affecting Angiogenesis 404

7.9 The Competition Through Close Mechanistic Approximation of Cancer Drugs Affecting Angiogenesis 427

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy 438

8.1 Small Molecules 440

8.1.1 Background 440

8.1.2 Target Strategies of Small Molecule Drugs 441

8.2 Peptide/Protein Drugs 458

8.2.1 Background 458

8.2.2 Target Strategies of Peptide and Protein Drugs 459

8.3 Antibodies and Antibody-like Structures 465

8.3.1 Background 465

8.3.2 Target Strategies of Antibody Drugs 465

8.4 Nucleic Acid Therapies 469

8.4.1 Background 469

8.4.2 Target Strategies of Nucleic Acid Drugs 470

8.5 Gene Therapy 472

8.5.1 Background 472

8.5.2 Target Strategies of Gene Therapy Drugs 472

8.6 Drug Delivery and Nanotechnology 475

8.6.1 Background 475

8.6.2 Target Strategies of Reformulated Drugs 475

8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 478

9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology 486

9.1 Acute Lymphocytic Leukemia 489

9.2 Acute Myelogenous Leukemia 490

9.3 Adrenal Cancer 493

9.4 B-cell Lymphoma 495

9.5 Basal Cell Cancer 496

9.6 Biliary Cancer 497

9.7 Bladder Cancer 498

9.8 Bone Cancer 501

9.9 Brain Cancer 502

9.10 Breast Cancer 506

9.11 Cancer (general) 515

9.12 Cancer Diagnosis 516

9.13 Carcinoid 517

9.14 Cervical Cancer 519

9.15 Chemotherapy-induced Alopecia 520

9.16 Chemotherapy-induced Infection 520

9.17 Chronic Lymphocytic Leukemia 521

9.18 Chronic Myelogenous Leukemia 522

9.19 CNS Cancer 524

9.20 Colorectal Cancer 524

9.21 Endometrial Cancer 534

9.22 Fallopian Tube Cancer 536

9.23 Fibro Sarcoma 538

9.24 Gastrointestinal Cancer (general) 539

9.25 Gastrointestinal Stomach Cancer 542

9.26 Gastrointestinal Stromal Cancer 545

9.27 Head and Neck Cancer 547

9.28 Hodgkin's Lymphoma 551

9.29 Kaposi's Sarcoma 551

9.30 Leiomyo Sarcoma 552

9.31 Leukemia (general) 553

9.32 Lipo Sarcoma 555

9.33 Liver Cancer 556

9.34 Lung Cancer (general) 561

9.35 Lymphoma (general) 563

9.36 Mast Cell Leukemia 565

9.37 Melanoma 566

9.38 Mesothelioma 571

9.39 Myelodysplastic Syndrome 573

9.40 Myeloma 575

9.41 Nasopharyngeal Cancer 578

9.42 Neuroendocrine Cancer (general) 579

9.43 Neuroendocrine Cancer (pancreatic) 580

9.44 Non-Hodgkin's Lymphoma 582

9.45 Non-Small Cell Lung Cancer 584

9.46 Oesophageal Cancer 592

9.47 Oral Cancer 594

9.48 Osteo Sarcoma 594

9.49 Ovarian Cancer 595

9.50 Pancreatic Cancer 600

9.51 Peritoneal Cancer 604

9.52 Prostate Cancer 606

9.53 Renal Cancer 611

9.54 Sarcoma (general) 615

9.55 Small Cell Lung Cancer 618

9.56 Soft Tissue Sarcoma 623

9.57 Solid Tumor 625

9.58 Squamous Cell Cancer 627

9.59 Synovial Sarcoma 628

9.60 T-cell Lymphoma 629

9.61 Testicular Cancer 630

9.62 Thyroid Cancer 631

9.63 Unspecified 636

9.64 Vaccine adjunct 643

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 644

10.1 Competitive Fall-Out Assessment 644

10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 646

10.3 Abbott 648

10.4 Abraxis BioScience 656

10.5 Acceleron Pharma 661

10.6 Access 664

10.7 ACT Biotech 667

10.8 Active Biotech 672

10.9 Adherex 675

10.10 Advanced Cancer Therapeutics 680

10.11 Advantagene 683

10.12 Advaxis 687

10.13 Advenchen 690

10.14 Aeterna Zentaris 693

10.15 Agennix 697

10.16 Aida Pharmaceuticals 700

10.17 Alnylam 703

10.18 Ambit Biosciences 706

10.19 Ambrilia Biopharma 710

10.20 Amgen 713

10.21 Amphora 719

10.22 Angiogen 723

10.23 Angiogenex 726

10.24 Angstrom Pharmaceuticals 729

10.25 Ansaris 733

10.26 Antisoma 737

10.27 Arana Therapeutics 740

10.28 Ariad 743

10.29 Arno Therapeutics 749

10.30 ArQule 752

10.31 Array BioPharma 756

10.32 Astex Therapeutics 759

10.33 AstraZeneca 762

10.34 Attenuon 768

10.35 Austrianova 773

10.36 Bayer 776

10.37 BioAlliance Pharma 781

10.38 BioAxone 784

10.39 Biocompatibles 787

10.40 Boehringer Ingelheim 791

10.41 Bolder BioTechnology 795

10.42 Bristol-Myers Squibb 799

10.43 CDG Therapeutics 807

10.44 Celecure 810

10.45 Celgene 813

10.46 Cell Therapeutics 816

10.47 CellCeutix 819

10.48 Cellmid 822

10.49 Cephalon 825

10.50 ChemoCentryx 828

10.51 Chemokine Therapeutics 831

10.52 China Sky One Medical 834

10.53 Choongwae 837

10.54 Circadian Technologies 840

10.55 Cue Biotech 843

10.56 Curis 846

10.57 Cyclacel 849

10.58 Cytochroma 852

10.59 Deciphera Pharmaceuticals 855

10.60 Dendreon 859

10.61 Dyax 862

10.62 Eisai 865

10.63 Eli Lilly 871

10.64 Endocyte 879

10.65 EntreMed 882

10.66 Exelixis 890

10.67 ExonHit Therapeutics 897

10.68 Facet Biotech 901

10.69 Five Prime Therapeutics 904

10.70 GammaCan 907

10.71 Genmab 911

10.72 GlaxoSmithKline 917

10.73 GlycoGenesys 922

10.74 Green Cross 925

10.75 Hoffmann-La Roche 929

10.76 Hy BioPharma 936

10.77 Idera Pharmaceuticals 939

10.78 ImClone Systems 943

10.79 ImmunoGen 946

10.80 ImmuPharma 949

10.81 Introgen Therapeutics 952

10.82 Isis Pharmaceuticals 956

10.83 Johnson & Johnson 959

10.84 KAI Pharmaceuticals 965

10.85 Karus Therapeutics 968

10.86 Kirin Pharma 971

10.87 Kringle Pharma 974

10.88 Kyowa Hakko Kirin 977

10.89 Lee's Pharmaceutical 981

10.90 Lorus Therapeutics 984

10.91 MAT Biopharma 987

10.92 MediGene 990

10.93 Merck & Co 994

10.94 Merck KGaA 997

10.95 Mersana Therapeutics 1001

10.96 MethylGene 1004

10.97 Micromet 1007

10.98 MolMed 1010

10.99 Morvus Technology 1013

10.100 NewSouth Innovations 1016

10.101 Non-industrial Sources 1019

10.102 Novartis 1022

10.103 Novelix 1037

10.104 Oasmia 1040

10.105 Onconova 1043

10.106 OncoTherapy Science 1046

10.107 Oncothyreon 1050

10.108 OSI Pharmaceuticals 1053

10.109 Oxford BioMedica 1058

10.110 OXiGENE 1061

10.111 Pepscan Therapeutics 1065

10.112 PepTx 1069

10.113 Peregrine Pharmaceuticals 1072

10.114 Pfizer 1076

10.115 Pharmacopeia 1089

10.116 Pharmacyclics 1092

10.117 PharmaMar 1095

10.118 Pharminox 1099

10.119 Philogen 1102

10.120 PhiloGene 1105

10.121 Pierre Fabre 1108

10.122 Progen 1112

10.123 Protein Sciences 1115

10.124 PTC Therapeutics 1118

10.125 Receptor BioLogix 1122

10.126 Regeneron 1126

10.127 Rexahn 1131

10.128 Rigel 1134

10.129 Sanofi-Aventis 1137

10.130 Santaris Pharma 1140

10.131 Scancell 1144

10.132 SciClone Pharmaceuticals 1147

10.133 Semafore Pharmaceuticals 1150

10.134 Simcere Pharmaceuticals 1153

10.135 Spear Therapeutics 1158

10.136 SRI International 1161

10.137 SuperGen 1164

10.138 Switch Pharma 1167

10.139 SynDevRx 1170

10.140 Tau Therapeutics 1173

10.141 ThromboGenics 1177

10.142 Tigris Pharmaceuticals 1180

10.143 ToolGen 1183

10.144 TopoTarget 1187

10.145 Tracon Pharmaceuticals 1190

10.146 UCB 1193

10.147 VBL Therapeutics 1198

10.148 Wilex 1201

10.149 Wyeth 1205

10.150 Xerion 1208

11 Disclaimer 1212

12 Drug Index 1213

13 Company Index 1221

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 306

Figure 2: The Drug-Target Interactions of Angiogenesis Affecting Cancer Drugs - Large Cluster 308

Figure 3: The Drug-Target Interactions of Angiogenesis Affecting Cancer Drugs - Smaller Clusters 309

Figure 4: Head-to-Head Targeting Interactions of Angiogenesis Affecting Cancer Drugs – Large Clusters 310

Figure 5: Head-to-Head Targeting Interactions of Angiogenesis Affecting Cancer Drugs – Smaller Clusters 311

Figure 6: Distribution of Compound Strategies among Cancer Drugs Affecting Angiogenesis 478

Figure 7: Primary Sub-cellular Localization of Drug Targets 479

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 6

Table 2: Breakdown of the Included Cancer Pipeline of Angiogenesis Affecting Drugs by Stage of Development 35

Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Cancer 35

Table 4: Overview of Drug Target Strategy Themes 40

Table 5: Terminally Ceased Targets of Cancer Drugs Affecting Angiogenesis 41

Table 6: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 294

Table 7: Identity of Cancer Drug Targets with Available Biological Structures 298

Table 8: Number of Target-Target Interactions among Targets of Cancer Drugs 302

Table 9: Available Protein Expression Profiles of Cancer Drug Targets 312

Table 10: Pathway Summary 318

Table 11: Drug Targets without any Identified Assigned Pathways 318

Table 12: Pathway Profiles According to BioCarta of Cancer Drug Targets 320

Table 13: Pathway Profiles According to KEGG of Cancer Drug Targets 339

Table 14: Pathway Profiles According to NetPath of Cancer Drug Targets 362

Table 15: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 367

Table 16: Top Competitive Target Strategies of Cancer Drugs Affecting Angiogenesis 368

Table 17: Target Strategies of Terminated Cancer Drugs Affecting Angiogenesis 370

Table 18: New and Unique Target Strategies of Registered to Marketed Cancer Drugs Affecting Angiogenesis 374

Table 19: The Competition Through Close Mechanistic Approximation Between Registered to Marketed Cancer Drugs Affecting Angiogenesis 375

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Cancer Drugs Affecting Angiogenesis 376

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Cancer Drugs Affecting Angiogenesis 378

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Cancer Drugs Affecting Angiogenesis 380

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Drugs Affecting Angiogenesis 383

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Cancer Drugs Affecting Angiogenesis 388

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Drugs Affecting Angiogenesis 392

Table 26: New and Unique Target Strategies in Preclinical Development of Cancer Drugs Affecting Angiogenesis 397

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Drugs Affecting Angiogenesis 399

Table 28: New and Unique Target Strategies in Unknown Developmental Stage of Cancer Drugs Affecting Angiogenesis 401

Table 29: The Competition Through Close Mechanistic Approximation Between Cancer Drugs Affecting Angiogenesis with No Developmental Data in Cancer 402

Table 30: The Progression, Maturity and Competitive Comparison of Target Strategies of Cancer Drugs Affecting Angiogenesis 404

Table 31: The Competition Through Close Mechanistic Approximation Among All Cancer Drugs Affecting Angiogenesis 427

Table 32: Overview of Compound Strategy Competition Among Drugs in Oncology Affecting Angiogenesis 439

Table 33: Overview of the Competitive Landscape of Small Molecule Drugs Affecting Angiogenesis in Cancer 441

Table 34: The Competition Through Close Mechanistic Approximation between Small Molecule Drugs Affecting Angiogenesis in Cancer 442

Table 35: Competitive Comparison of Target Strategies of Small Molecule Drugs Affecting Angiogenesis in Cancer 450

Table 36: Overview of the Competitive Landscape of Peptide Based Drugs Affecting Angiogenesis in Cancer 459

Table 37: The Competition Through Close Mechanistic Approximation between Peptide Based Drugs Affecting Angiogenesis in Cancer 460

Table 38: Competitive Comparison of Target Strategies of Peptide Based Drugs Affecting Angiogenesis in Cancer 460

Table 39: Overview of the Competitive Landscape of Protein Based Drugs Affecting Angiogenesis in Cancer 462

Table 40: The Competition Through Close Mechanistic Approximation between Protein Based Drugs Affecting Angiogenesis in Cancer 463

Table 41: Competitive Comparison of Target Strategies of Protein Based Drugs Affecting Angiogenesis in Cancer 463

Table 42: Overview of the Competitive Landscape of Antibody Based Drugs Affecting Angiogenesis in Cancer 465

Table 43: The Competition Through Close Mechanistic Approximation between Antibody Drugs Affecting Angiogenesis in Cancer 466

Table 44: Competitive Comparison of Target Strategies of Antibody Based Drugs Affecting Angiogenesis in Cancer 467

Table 45: Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs Affecting Angiogenesis in Cancer 470

Table 46: The Competition Through Close Mechanistic Approximation between Nucleic Acid Therapy Drugs Affecting Angiogenesis in Cancer 471

Table 47: Competitive Comparison of Target Strategies of Nucleic Acid Drugs Affecting Angiogenesis in Cancer 471

Table 48: Vectors in Gene Therapy 472

Table 49: Overview of the Competitive Landscape of Gene Therapy based Drugs Affecting Angiogenesis in Cancer 472

Table 50: The Competition Through Close Mechanistic Approximation between Gene Therapy Based Drugs Affecting Angiogenesis in Cancer 473

Table 51: Competitive Comparison of Target Profiles of Gene Therapy Based Drugs Affecting Angiogenesis in Cancer 474

Table 52:Overview of the Competitive Landscape of Reformulated Drugs Affecting Angiogenesis in Cancer 475

Table 53: The Competition Through Close Mechanistic Approximation between Reformulated Drugs Affecting Angiogenesis in Cancer 476

Table 54: Competitive Comparison of Target Strategies of Reformulated Drugs Affecting Angiogenesis in Cancer 477

Table 55: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Drug Targets 479

Table 56 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs 487

Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia 489

Table 58: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia 490

Table 59: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 492

Table 60: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer 493

Table 61: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs 494

Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma 495

Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer 496

Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer 497

Table 65: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer 498

Table 66: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 500

Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer 501

Table 68: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer 502

Table 69: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 504

Table 70: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer 506

Table 71: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 511

Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general) 515

Table 73: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer Diagnosis 516

Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid 517

Table 75: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 518

Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer 519

Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemotherapy-induced Alopecia 520

Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemotherapy-induced Infection 520

Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia 521

Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia 522

Table 81: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer 524

Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer 525

Table 83: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 530

Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer 534

Table 85: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs 535

Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer 536

Table 87: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 537

Table 88: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma 538

Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general) 539

Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 540

Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer 542

Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 544

Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer 545

Table 94: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 546

Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer 547

Table 96: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 549

Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin's Lymphoma 551

Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi's Sarcoma 551

Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma 552

Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general) 553

Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma 555

Table 102: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer 556

Table 103: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 559

Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general) 561

Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general) 563

Table 106: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia 565

Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma 566

Table 108: The Competition through Close Mechanistic Approximation between Melanoma Drugs 569

Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma 571

Table 110: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 572

Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome 573

Table 112: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma 575

Table 113: The Competition through Close Mechanistic Approximation between Myeloma Drugs 577

Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer 578

Table 115: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general) 579

Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 580

Table 117: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs 581

Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin's Lymphoma 582

Table 119: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer 584

Table 120: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 588

Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer 592

Table 122: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer 594

Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma 594

Table 124: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer 595

Table 125: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 598

Table 126: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer 600

Table 127: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 602

Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer 604

Table 129: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 605

Table 130: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer 606

Table 131: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 609

Table 132: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer 611

Table 133: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 612

Table 134: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general) 615

Table 135: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 617

Table 136: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer 618

Table 137: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 622

Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma 623

Table 139: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 624

Table 140: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor 625

Table 141: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 626

Table 142: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer 627

Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma 628

Table 144: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma 629

Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer 630

Table 146: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer 631

Table 147: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 633

Table 148: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified Cancer Indication 636

Table 149: The Competition through Close Mechanistic Approximation between Unspecified Cancer Drugs 640

Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct 643

Table 151: Example of a Competitive Fall-Out Table (Modified, Platelet glycoprotein 4 trageting drugs) 645

Table 152: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology 646

Table 153: Abbott's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 648

Table 154: Abraxis BioScience's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 656

Table 155: Acceleron Pharma's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 661

Table 156: Access' Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 664

Table 157: ACT Biotech's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 667

Table 158: Active Biotech's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 672

Table 159: Adherex's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 675

Table 160: Advanced Cancer Therapeutics' Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 680

Table 161: Advantagene's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 683

Table 162: Advaxis' Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 687

Table 163: Advenchen's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 690

Table 164: Aeterna Zentaris' Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 693

Table 165: Agennix's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 697

Table 166: Aida Pharmaceuticals' Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 700

Table 167: Alnylam's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 703

Table 168: Ambit Biosciences' Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 706

Table 169: Ambrilia Biopharma's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 710

Table 170: Amgen's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 713

Table 171: Amphora's Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 719

Table 172: Angiogen's Included Angiogenesis Targeting Drug Pipeline

To order this report:

Drug Discovery and Development Industry: Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com